Brief: GeNeuro Announces Positive Results From Temelimab Phase 1 High-Dose Clinical Trial

Geneuro SA

21/01/2019 17:37

Jan 21 (Reuters) - GENEURO SA  GNRO.PA :
    * GENEURO ANNOUNCES POSITIVE RESULTS FROM TEMELIMAB (GNBAC1)
PHASE
1 HIGH-DOSE CLINICAL TRIAL
    * TEMELIMAB'S ROBUST SAFETY AND TOLERABILITY PROFILE
CONFIRMED
    * HIGH-DOSE REGIMEN FULLY VALIDATED BY PHARMACOKINETIC DATA
    * ENABLES HIGHER DOSES OR FRONT-LOADING TO BE CONSIDERED FOR
FUTURE CLINICAL STUDIES
    * DRUG CANDIDATE'S OVERALL PROFILE ENHANCED AHEAD OF A
POSSIBLE
PARTNERSHIP TO CONTINUE GLOBAL DEVELOPMENT OF TEMELIMAB AS A
TREATMENT FOR MULTIPLE SCLEROSIS (MS)

Source text for Eikon:  ID:nBw4WHdbTa 
Further company coverage:  GNRO.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com;))